TY - JOUR
T1 - Impact of a patient-tailored complementary/integrative medicine programme on disturbed sleep quality among patients undergoing chemotherapy
AU - Kerner, Hilit
AU - Samuels, Noah
AU - Ben Moshe, Shlomi
AU - Sharabi, Ilanit Shalom
AU - Ben-Arye, Eran
N1 - Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2020. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Objectives The present study examined the impact of a patient-tailored complementary/integrative medicine (CIM) programme on sleep quality in patients undergoing chemotherapy for breast and gynaecological cancer. Methods Study participants received standard supportive care, with or without weekly CIM treatments. Disturbed sleep quality was defined as a score of ≥4 on the Edmonton Symptom Assessment Scale (ESAS) or a score of ≥3 on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Adherence to integrative care was defined as attending ≥4 CIM treatments, with ≤30 days between each session. Results Of 388 eligible patients, 264 (68%) reported disturbed sleep quality. Baseline-to-follow up assessment (at 6 weeks) was optimal for 104 patients in the treatment group and for 76 controls, with 75 of treated patients found to be adherent to the CIM intervention. Sleep-related ESAS scores improved more significantly in treated patients (p=0.008), as did sleep-related concerns on EORTC (treatment group, p=0.026). Conclusions A patient-tailored CIM programme may improve sleep quality and related concerns among patients with breast and gynaecological cancer undergoing chemotherapy. Further research is needed to better understand the impact of CIM on sleep quality in this patient population. Trial registration number NCT01860365.
AB - Objectives The present study examined the impact of a patient-tailored complementary/integrative medicine (CIM) programme on sleep quality in patients undergoing chemotherapy for breast and gynaecological cancer. Methods Study participants received standard supportive care, with or without weekly CIM treatments. Disturbed sleep quality was defined as a score of ≥4 on the Edmonton Symptom Assessment Scale (ESAS) or a score of ≥3 on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Adherence to integrative care was defined as attending ≥4 CIM treatments, with ≤30 days between each session. Results Of 388 eligible patients, 264 (68%) reported disturbed sleep quality. Baseline-to-follow up assessment (at 6 weeks) was optimal for 104 patients in the treatment group and for 76 controls, with 75 of treated patients found to be adherent to the CIM intervention. Sleep-related ESAS scores improved more significantly in treated patients (p=0.008), as did sleep-related concerns on EORTC (treatment group, p=0.026). Conclusions A patient-tailored CIM programme may improve sleep quality and related concerns among patients with breast and gynaecological cancer undergoing chemotherapy. Further research is needed to better understand the impact of CIM on sleep quality in this patient population. Trial registration number NCT01860365.
KW - breast cancer
KW - complementary/integrative medicine (CIM)
KW - gynecological cancer
KW - insomnia
KW - integrative oncology.
KW - sleep disorders
UR - http://www.scopus.com/inward/record.url?scp=85050748643&partnerID=8YFLogxK
U2 - 10.1136/bmjspcare-2017-001351
DO - 10.1136/bmjspcare-2017-001351
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28710110
AN - SCOPUS:85050748643
SN - 2045-435X
VL - 10
JO - BMJ Supportive and Palliative Care
JF - BMJ Supportive and Palliative Care
IS - 3
M1 - e21
ER -
